Month: April 2021

Nasdaq CopenhagenLondon Stock ExchangeOther stakeholders 28 April 2021 Ringkjøbing Landbobank’s report for the first quarter of 2021 With core earnings of DKK 368 million and profit before tax of DKK 354 million, the bank delivers a good start to 2021. The profit before tax is equivalent to a return of 17.4% p.a. on equity. Core earnings(DKK million) Q12021 Q12020 2020 2019 2018 2017 2016Total core income 600 541 2,179 2,116 2,001 1,917 1,861Total expenses and depreciation 203 198 788 805 866 845 815Core earnings before impairment charges for loans 397 343 1,391 1,311 1,135 1,072 1,046Impairment charges for loans etc. -29 -75 -223 -100 -43 -70 -211Core earnings 368 268 1,168 1,211 1,092 1,002 835Result for the portfolio etc. -10 -70 -9 +49 +77 +84 +78Special costs 4 4 15 15 217 22 22Profit before tax 354 194 1,144 1,245 952 1,064 891Highlights...

Nasdaq CopenhagenLondon Stock ExchangeØvrige interessenter 28. april 2021 Ringkjøbing Landbobanks kvartalsrapport for 1. kvartal 2021 Banken realiserer med et basisresultat på 368 mio. kroner og et resultat før skat på 354 mio. kroner en god start på 2021. Resultatet før skat forrenter egenkapitalen med 17,4% p.a. Basisresultat(mio. kroner) 1. kvt.2021 1. kvt.2020 2020 2019 2018 2017 2016Basisindtjening i alt 600 541 2.179 2.116 2.001 1.917 1.861Samlede udgifter og afskrivninger 203 198 788 805 866 845 815Basisresultat før nedskrivninger på udlån 397 343 1.391 1.311 1.135 1.072 1.046Nedskrivninger på udlån m.v. -29 -75 -223 -100 -43 -70 -211Basisresultat 368 268 1.168 1.211 1.092 1.002 835Beholdningsresultat m.v. -10 -70 -9 +49 +77 +84 +78Særlige omkostninger 4 4 15 15 217 22 22Resultat før skat 354 194 1.144 1.245 952 1.064 8911....

Cardiovascular diseases are responsible for 17.9 million deaths every year¹, a third of all deaths globally² Roche announces five new intended uses for key cardiac biomarkers to help identify cardiovascular risk, better diagnose patients and support early treatment Early diagnosis and treatment can contribute to saving or improving people’s lives and could help healthcare systems save moneyBasel, 28 April 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced a series of five new intended uses for two key cardiac biomarkers using the Elecsys® technology: high sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP). These gold standard biomarkers³ have proven to be successful in supporting cardiovascular disease management and can help clinicians diagnose heart attacks⁴ (cTnT-hs)...

Regulated information Intermediate declaration by the Board of Directors Ieper, Belgium – April 28th, 2021, 07.00 hrs CET Dear, Please find herewith the link to our most recent press release: www.melexis.com/en/news/2021/financial/melexis-q1-2021-results AttachmentPR_ENG_Melexis_Q1 2021

Gereglementeerde informatie  Tussentijdse verklaring, opgesteld door de Raad van BestuurIeper, België – 28 april 2021, 07.00 uur CET Geachte, hieronder vindt u de link naar ons meest recente persbericht: www.melexis.com/nl/news/2021/financial/melexis-q1-2021-results BijlagePR_NL_Melexis_Q1 2021

Information réglementée Déclaration intermédiaire par le Conseil d’administrationYpres, Belgique – le 28 avril 2021, 07.00 H. CET Veuillez trouver ici le lien vers notre dernier communiqué de presse: www.melexis.com/fr/news/2021/financial/melexis-q1-2021-results Pièce jointePR_FR_Melexis_Q1 2021

Borregaard’s operating revenues reached NOK 1,419 million (NOK 1,372 million)² in the 1st quarter of 2021. EBITDA¹ increased to NOK 302 million (NOK 242 million). All business areas improved their results compared with the corresponding quarter in 2020. The net currency impact on EBITDA¹ was negative compared with the 1st quarter of 2020. EBITDA¹ in BioSolutions improved as a result of price increases for certain biopolymer applications and reduced costs. The BioMaterials result improved due to high deliveries of speciality cellulose and a favourable product mix which more than compensated for lower sales prices. In Fine Chemicals, the effect of low deliveries was more than offset by a favourable product mix for fine chemical intermediates and a high production volume of bioethanol. Profit before tax was NOK 176 million (NOK 111 million)....

Norwegian Finans Holding (the NFH Group) reported profit after tax in the first quarter of 2021 of NOK 396.8 million, compared with NOK 436.2 million in the fourth quarter of 2020 and MNOK 368.0 in the first quarter last year. The decrease from the previous quarter is mainly caused by lower interest income due to volume and currency effects, and VISA dividend received in the fourth quarter, partly offset by seasonal provision income from kick-back in the current quarter. Return on equity was 14.3%, compared with 16.4% in the previous quarter. The return on assets was 2.6%, compared with 2.7% in the previous quarter. A dividend of NOK 6 per share was approved at the Annual General Meeting (AGM) on April 27th, with NOK 5 per share to be paid on May 6 and the Board of Directors has been granted authorization to pay the remaining NOK 1 per...

Press Release April 28, 2021 – N° 10 First quarter 2021 results SCOR demonstrates its shock-absorbing capacityonce again in Q1 2021 In Q1 2021, SCOR’s financial results have been impacted by the unique combination of known and modelled Covid-19 claims development and a series of large natural catastrophes, driven by a polar vortex causing Texas Winter Storm Uri. Covid-19 claims are manageable, developing as expected and tracking closely in line with what was previously communicated1. In Q1 2021, Covid-19 impact stands on the Life side at EUR 162 million2, of which EUR 145 million comes from the U.S. mortality portfolio, and overall has been stable on the P&C side since December 31, 2020. The SCOR group continues to grow and to absorb shocks. SCOR records a net income of EUR 45 million in Q1 2021 and delivers a very high solvency...